Rett syndrome: randomized controlled trial of L-carnitine
- PMID: 10190267
- DOI: 10.1177/088307389901400306
Rett syndrome: randomized controlled trial of L-carnitine
Abstract
Rett syndrome is a severe neurodevelopmental disorder of unknown etiology, occurring almost exclusively in female patients. The etiology and functional significance of plasma carnitine deficiency seen in some patients with Rett syndrome is unknown. To investigate whether L-carnitine might be of benefit in Rett syndrome, a randomized, placebo-controlled, double-blind crossover trial of L-carnitine has been completed in 35 subjects. Eight-week treatment phases were completed for both a placebo and L-carnitine. Outcome was measured by parents/caregivers and at medical follow-up using three established tools: the Rett Syndrome Motor Behavioral Assessment, the Hand Apraxia Scale, and the Patient Well-Being Index. Analysis comparing change between baseline and week 8 of treatment for L-carnitine and the placebo showed that both parents/caregivers and medical follow-up detected improvements in the subjects' well-being. In addition, medical review showed an improvement on the Hand Apraxia Scale for a higher proportion of girls on L-carnitine. Identification of predictors of clinical improvement has been limited by the power of the study. These findings suggest that L-carnitine is of benefit in some patients with Rett syndrome. While L-carnitine did not lead to major functional changes in ability, the type of changes reported could still have a substantial impact on the girls and their families. Information is still needed, however, to determine if only subgroups of girls with the disorder are responsive to L-carnitine and the appropriate duration of therapy.
Similar articles
-
Medium-term open label trial of L-carnitine in Rett syndrome.Brain Dev. 2001 Dec;23 Suppl 1:S85-9. doi: 10.1016/s0387-7604(01)00346-1. Brain Dev. 2001. PMID: 11738848 Clinical Trial.
-
Effects of creatine supplementation in Rett syndrome: a randomized, placebo-controlled trial.J Dev Behav Pediatr. 2011 Jul-Aug;32(6):454-60. doi: 10.1097/DBP.0b013e31822177a8. J Dev Behav Pediatr. 2011. PMID: 21654506 Clinical Trial.
-
L-carnitine as a treatment for Rett syndrome.South Med J. 1993 Dec;86(12):1411-2. doi: 10.1097/00007611-199312000-00021. South Med J. 1993. PMID: 8272924
-
Rett syndrome: update of a 25 year follow-up investigation in Western Sweden--sociomedical aspects.Brain Dev. 2001 Dec;23 Suppl 1:S224-6. doi: 10.1016/s0387-7604(01)00373-4. Brain Dev. 2001. PMID: 11738877 Review.
-
Physical therapy intervention for individuals with Rett syndrome.ScientificWorldJournal. 2006 Oct 10;6:1314-38. doi: 10.1100/tsw.2006.187. ScientificWorldJournal. 2006. PMID: 17041720 Free PMC article. Review.
Cited by
-
L-Carnitine in the Treatment of Psychiatric and Neurological Manifestations: A Systematic Review.Nutrients. 2024 Apr 20;16(8):1232. doi: 10.3390/nu16081232. Nutrients. 2024. PMID: 38674921 Free PMC article.
-
Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update.Front Med (Lausanne). 2021 Aug 9;8:689042. doi: 10.3389/fmed.2021.689042. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34434943 Free PMC article. Review.
-
Rett Syndrome: Crossing the Threshold to Clinical Translation.Trends Neurosci. 2016 Feb;39(2):100-113. doi: 10.1016/j.tins.2015.12.008. Trends Neurosci. 2016. PMID: 26830113 Free PMC article. Review.
-
Rett syndrome: clinical review and genetic update.J Med Genet. 2005 Jan;42(1):1-7. doi: 10.1136/jmg.2004.027730. J Med Genet. 2005. PMID: 15635068 Free PMC article. Review.
-
Rett Syndrome: The Emerging Landscape of Treatment Strategies.CNS Drugs. 2024 Nov;38(11):851-867. doi: 10.1007/s40263-024-01106-y. Epub 2024 Sep 9. CNS Drugs. 2024. PMID: 39251501 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical